Literature DB >> 7104222

Assessment of bone marrow histology in Hodgkin's disease: correlation with clinical factors.

R Bartl, B Frisch, R Burkhardt, D Huhn, R Pappenberger.   

Abstract

Bone marrow biopsies of 491 untreated and 170 treated patients with Hodgkin's disease (HD) were investigated. Marrow involvement was found in 10% and 25% respectively. Positive biopsies were rare in clinical stages I and II (1% and 2%), but the incidence rose to 25% and 45% in stages III and IV. HD patients with nodular sclerosis in lymph node histology had a low incidence of bone marrow involvement (4%), while those with lymphocytic depletion had a high incidence (22%). Of nine clinical and six histological parameters tested, bone marrow involvement proved to be the most significant predictive factor indicating an unfavourable course. Moreover, classification of the bone marrow manifestations according to the degree of lymphocytic infiltration, proved to be simple, reproducible and prognostically significant. Normal haematopoietic tissue was found in only 20% of the negative biopsies of untreated patients. The remaining 80% were characterized by a variety of non-specific reactions. These included marrow hypoplasia and leukaemoid and exudative reactions each of which indicated a poor prognosis; and epithelioid-cell granulomas and lymphoid nodules which predicted favourable survival curves. Adequate bone marrow biopsy is a valuable part of the investigation of patients with HD, as both positive and negative biopsies provide information of prognostic significance.

Entities:  

Mesh:

Year:  1982        PMID: 7104222     DOI: 10.1111/j.1365-2141.1982.tb02790.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  9 in total

1.  Incidence and histological features of bone marrow involvement in malignant lymphomas.

Authors:  G Lambertenghi-Deliliers; C Annaloro; D Soligo; A Oriani; E Pozzoli; N Quirici; R Luksch; E E Polli
Journal:  Ann Hematol       Date:  1992-08       Impact factor: 3.673

2.  Clinico-pathologic profile of Hodgkin's lymphoma in a rural medical college.

Authors:  Bidyut Krishna Goswami; Supriya Sarkar; Sudipta Chakrabarti; Srikrishna Mondal; Amitabha Roy; Asit R Deb
Journal:  Indian J Hematol Blood Transfus       Date:  2009-01-11       Impact factor: 0.900

3.  Staging and follow up of patients with lymphoproliferative disorder.

Authors:  A N Stark
Journal:  J Clin Pathol       Date:  1993-03       Impact factor: 3.411

4.  Lymphoproliferations in the bone marrow: identification and evolution, classification and staging.

Authors:  R Bartl; B Frisch; R Burkhardt; K Jäger; R Pappenberger; G Hoffmann-Fezer
Journal:  J Clin Pathol       Date:  1984-03       Impact factor: 3.411

5.  Bone marrow trephine biopsy.

Authors:  B J Bain
Journal:  J Clin Pathol       Date:  2001-10       Impact factor: 3.411

6.  Focal lymphoid aggregates (nodules) in bone marrow biopsies: differentiation between benign hyperplasia and malignant lymphoma--a practical guideline.

Authors:  J Thiele; T K Zirbes; H M Kvasnicka; R Fischer
Journal:  J Clin Pathol       Date:  1999-04       Impact factor: 3.411

7.  Utility of bone marrow biopsy at diagnosis in pediatric Hodgkin's lymphoma.

Authors:  Melissa R Hines-Thomas; Scott C Howard; Melissa M Hudson; Matthew J Krasin; Sue C Kaste; Barry L Shulkin; Monika L Metzger
Journal:  Haematologica       Date:  2010-05-21       Impact factor: 9.941

Review 8.  Assessment of bone marrow involvement in patients with lymphoma: report on a consensus meeting of the Korean Society of Hematology Lymphoma Working Party.

Authors:  Yong Park; Byung Bae Park; Ji Yun Jeong; Wook Youn Kim; Seongsoo Jang; Bong Kyung Shin; Dong Soon Lee; Jae Ho Han; Chan-Jeoung Park; Cheolwon Suh; Insun Kim; Hyun-Sook Chi
Journal:  Korean J Intern Med       Date:  2016-11-01       Impact factor: 2.884

9.  Bone marrow examination in newly diagnosed Hodgkin's disease: current practice in the United Kingdom.

Authors:  M R Howard; P R Taylor; H H Lucraft; M J Taylor; S J Proctor
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.